Avelumab for Advanced Merkel Cell Carcinoma in the Netherlands; A Nationwide Survey Abstract #2796

Introduction: Merkel cell carcinoma (MCC) is a rare, tumor of the skin associated with high recurrence rates and poor survival. Clinical trials have shown activity of checkpoint inhibitors targeting programmed death-(ligand)-1 (PD-(L)1). Avelumab is the only PD-L1 inhibitor that has been approved in the Netherlands for advanced/metastatic MCC (mMCC).
Aim(s): To report the Dutch real-world efficacy data of avelumab in patients (pts) with mMCC.
Materials and methods: All mMCC pts from 4 tertiary referral centers in the Netherlands from December 2016 were analysed. Pts were included in this analysis if they had received avelumab for mMCC, regardless of other previous lines of therapy. Data were collected retrospectively and followed up prospectively after initiation of data collection. Primary endpoints were response rate (RR) and duration of response (DOR), secondary endpoints were progression free survival (PFS), overall survival (OS) and toxicity. Toxicity was evaluated according to CTCAE version 5.0.
Conference: 17th Annual ENETS Conference (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD Sonja Levy

To read results and conclusion, please login ...

Further abstracts you may be interested in

#69 Frequent biological association of Merkel cell polyomavirus with Merkel cell carcinomas
Introduction: Merkel cell polyomavirus (MCPyV) DNA has been detected by PCR in 75–100% of Merkel cell carcinomas (MCC), an aggressive neuroendocrine skin cancer. MCPyV is a 5.4 kb DNA virus that expresses tumor (T) antigen in tumor tissues.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Ernst-Jan M Speel
#634 Merkel Cell Carcinoma in a Nine-Year-Old Girl
Introduction: Merkel cell carcinoma (MCC) of the skin is a rare neuroendocrine tumor characterized by its rapid growth and aggressive clinical behavior. MCC is a typical tumor of older age (average age is 65 years). In children and adolescents less than 20 years of age, it is extremely rare. Information regarding MCC in childhood can be found in the literature only in the form of individual case reports. Due to the rarity of MCC in the young population, any clinical studies or treatment recommendations in these patients are missing.
Conference: 10th Annual ENETS Conference (2013)
Category: Clinical cases/reports
Presenting Author: MD, PhD Viera - Bajciova
Authors: Bajciova V, Kren L, Sterba J, Prasek J, ...
#703 Cutaneous Merkel Cell Carcinoma Treatment: Our Experience
Introduction: Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor of the skin.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Dr Francesca Bruder
Authors: Bruder F, Barca M, Porcu S G, Dessena M, ...
#1129 Expression and Clinical Significance of Merkel Cell Polyomavirus Large T Antigen in Merkel Cell Carcinoma
Introduction: Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer that is often associated with Merkel cell polyomavirus (MCPyV) infection. MCPyV expression and its relationship with clinical features and prognosis in MCC remain unclear.
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: Vera Delektorskaya
#1375 Merkel Cell Carcinoma of the Knee Treated with Somatostatin Analogue and Radiotherapy: A Case Report
Introduction: Merkel cell carcinoma (MCC) is a rare and aggressive primary cutaneous neuroendocrine malignancy. Chemotherapy with cisplatin (CDDP) and etoposide (VP16) is an effective treatment for metastatic MCC.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Ivana Puliafito
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team